• Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
  • The company has also announced a new chronic kidney disease research program
  • CEO Chris Moreau sat down with Shoran Devi to discuss the news
  • Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
  • Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.

Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.

The company has also announced a new chronic kidney disease research program.

CEO Chris Moreau sat down with Shoran Devi to discuss the news.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.

More From The Market Online

@ the Bell: Stocks level-out ahead of Easter long weekend

A rebound in oil prices and growth in metal prices helped push Canada’s main stock index higher as investors await economic data.
Bitcoin and cryptocurrency investing concept

U.S. spot Bitcoin ETFs are live – what happens to Canada’s crypto ETFs?

Three since the first spot Bitcoin ETF was introduced in Canada, these funds are finding formidable competition from U.S. counterparts.

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.